RPG Life Sciences Limited (NSE:RPGLIFE)

Market Cap	38.95B
Revenue (ttm)	6.66B
Net Income (ttm)	2.15B
Shares Out	16.54M
EPS (ttm)	130.25
PE Ratio	18.08
Forward PE	n/a
Dividend	20.00 (0.85%)
Ex-Dividend Date	Jun 27, 2025

Volume	11,359
Average Volume	21,136
Open	2,367.50
Previous Close	2,345.10
Day's Range	2,312.00 - 2,394.80
52-Week Range	1,835.00 - 2,744.80
Beta	-0.37
RSI	53.09
Earnings Date	Jan 28, 2026

About RPG Life Sciences

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 1,331
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: RPGLIFE

Financial Performance

In 2024, RPG Life Sciences's revenue was 6.53 billion, an increase of 12.26% compared to the previous year's 5.82 billion. Earnings were 1.83 billion, an increase of 109.03%.